The ability of bio-pharmaceutical manufacturers to deliver quality drug products during challenging market conditions is critical for ensuring sustainability over the long run. The COVID-19 pandemic underscored the need to transform the traditional bio-pharmaceutical supply chain to have greater agility and resiliency during market swings and periods of volatility.

Pharmaceutical companies, CDMOs and CMOs face growing pressures to deliver more products at a lower cost while ensuring the quality and security of supply. Advanced PAT technologies address these challenges by increasing saleable product through more consistent quality, higher yields and greater throughput. In addition, digitalization advances such as extensive connectivity, increased and elastic computing power, and advanced analytics have all continued to strengthen the accessibility and power of PAT to accelerate market growth.

Pharma and biotech companies face a pivotal next step in addressing the increased complexity of production while balancing mounting cost pressures with the need to ensure product quality, security of supply and regulatory compliance.

If faced with inhomogeneous blends, manufacturers lose money and valuable time. Not to mention the possible risks of reblends and regulatory citations.

Batch processing requires supremely accurate monitoring to ensure successful batch completion. In the case of deviations, the ability to prevent unwanted process behavior from happening is critical to ensure successful batches. The Camo solution for batch monitoring uses batch trajectory trending with smarter deviation detection to anticipate the process flow, so operators have time to act and can stay on top of production to ensure product quality and reduce waste.

The PAT (Process Analytical Technology) market is on track to more than double in size by 2023, yet many organizations have not unlocked PAT’s full potential. Watch this on-demand webinar to find out the drivers behind this growth, and how to assess and fast-track your PAT maturity.